Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Iovance Biotherapeutics, Inc.

NASDAQ: IOVA · Life Sciences · 7 alerts · CIK 1425205

Share price
$7.55Close, Nov 16
Market cap
$3.49B
Shares outstanding
462.66MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Iovance Biotherapeutics, Inc. filings on SEC EDGAR ↗

9:55 AM ET
Earnings Call ▶ Call

Iovance Biotherapeutics Earnings Call: Key Takeaways

Iovance delivered record Q3 revenue of $122 million and 60% margins, driven by strong Amtagvi adoption and a cash runway extended into 2029.

Call
Nov 5, 2026, 8:30 AM ET
5:01 PM ET 8-K
Clinical Trial Data

Iovance Biotherapeutics Clinical Trial Data

Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.